Leqvio Sales Still Lag But Novartis Is Playing The Long Game
Brings In Just $22m In Q2
The twice-yearly cholesterol injectable approved in Europe 18 months ago is still not making any commercial headway but Novartis's CEO Vas Narasimhan has stressed that the groundwork for access to and education about Leqvio is being firmly laid.
You may also be interested in...
The company announced a respectable increase in second quarter sales and expects to announce topline results within the next three weeks for the Phase III trial of Onpattro in ATTR-CM.
Sandoz has been able to hike its previously flat full-year annual guidance following an upward trajectory for the company, especially in Europe and the US. One analyst pondered whether this suggested the “emergence of a bottom in the US generics sector” during the second half of the year.
Faced with a scarily short cash runway and an ongoing expensive mid-stage study of an allogeneic cell therapy for the treatment of delayed-union bone fractures, Bone Therapeutics has found a saviour in France's Medsenic.